Popular Articles

$19 Million To Washington University Scientists To Decode Microbe DNA And Explore Links To Disease
The National Institutes of Health (NIH) has awarded scientists at Washington University School of Medicine in St. Louis four grants totaling $19 million to explore the trillions of microbes that inhabit the human body and determine how they contribute to good health and disease.
generic viagra online
Nexavar® In Combination With Chemotherapy Shown To Extend Progression-Free Survival In Patients With Advanced Breast Cancer
Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. announced that their first cooperative group-sponsored randomized Phase II trial in advanced metastatic breast cancer met its primary endpoint of progression-free survival. The study evaluated Nexavar® (sorafenib) tablets in combination with the oral chemotherapeutic, capecitabine, in patients with locally advanced or metastatic HER-2 negative breast cancer. Study findings demonstrated that the median progression-free survival was extended in patients treated with Nexavar and capecitabine compared to patients receiving capecitabine and placebo. These results were statistically significant (p-value = 0.0006). In this trial, the safety and tolerability of the combination was as expected and did not show any new or unexpected toxicities. A complete data analysis from this study is expected to be presented at an upcoming scientific meeting.
News of the day
2-Week Course Of Sleep Aid Increases CPAP Adherence In OSA Patients At 6 Months
New research suggests that patients newly diagnosed with obstructive sleep apnea (OSA) who use a short-course of the sleep aid, eszopiclone, when beginning continuous positive airway pressure (CPAP) therapy, are more adherent with therapy in six months.
Endocrinology

British Scientists Lead The Way In Dementia Research Despite Funding Gap

British scientists are leading the field at the International Conference of Alzheimer"s Disease, in Vienna (ICAD, 11 - 16 July). Researchers, backed by Alzheimer"s Society, are presenting a host of scientific projects from investigating new targets for drug treatments; studying the impact of mild head injuries on your risk of dementia to assessing people with dementia"s fitness to drive. ICAD is the biggest conference of the year looking at cause, cure, care and prevention of dementia. During the conference, Alzheimer"s Society researcher Dr Kidd, from Cardiff University, will present research on developing an immunotherapy against Alzheimer"s disease. Immunotherapy aims to treat diseases by inducing, enhancing, or suppressing an immune response and has been successfully used in cancer treatments. Dementia researchers are now testing various antibodies to see if they will act as potential treatments for dementia. Dr Fowler, from Edinburgh University, is presenting a poster describing work that assesses whether mild head injuries can increase a person"s risk of developing dementia. Epidemiological studies already suggest a link between head injuries and dementia and Dr Fowler will present further work on mice models that has been funded by Alzheimer"s Society. Last month Alzheimer"s Society joined British scientists and other charities to call for a tripling of government investment in dementia research. The charity revealed that despite the success of British researchers the UK government lags behind France, Germany and the US in dementia research funding and has no plans for the future. Professor Clive Ballard, Director of Research at Alzheimer"s Society, says, "It"s fantastic to see so many dementia researchers flying the flag for British research in Vienna. Dementia research in the UK is desperately underfunded. The government spends eight times less on dementia research than on cancer research but despite this lack of funding Britain continues to make important scientific discoveries. Just imagine what we could achieve if we tripled the funding for dementia research and developed a comprehensive plan. In the next ten years a million people will develop dementia; with the right investment dementia can be defeated. Alzheimer"s Society currently invests over ÷£6 million in cutting-edge health and social research, selected by leading experts, people with dementia and carers and is pleased to be showcasing this work at ICAD." Notes - International Conference of Alzheimer"s Disease (ICAD) is organised by Alzheimer"s Association. For more information visit http://www.alz.org/icad - One in three of us over 65 will die with dementia - 700,000 people in the UK have a form of dementia, more than half have Alzheimer"s disease. In less than 20 years nearly a million people will be living with dementia. This will soar to 1.7 million people by 2051 - Alzheimer"s Society champions the rights of people living with dementia and those who care for them. Alzheimer"s Society works in England, Wales and Northern Ireland - Alzheimer"s Society needs to raise money to support people today and to find a cure for tomorrow. You can donate now by calling 0845 306 0898 or visiting http://www.alzheimers.org.uk Alzheimer"s Society


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):